Lakeland Industries LAKE
- Market cap
- $95.2M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $191M
- −0% on a year ago
- Net margin
- −14.0%
- Free cash flow yield
- −0.7%
Lakeland Industries trades at 0.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $191M over the last twelve months, down 0% on a year earlier with a −14% net margin.
Charts
Financials
| Income statement | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $31.7M+12% | $31.2M+8% | $36.3M+27% | $38.5M+17% | $45.8M+45% | $46.6M+49% | $46.7M+29% | $52.5M+36% | $47.6M+4% | $45.8M−2% | $47.4M+1% | $50.1M−5% | |
| Cost of revenue | $18.3M+14% | $20M+11% | $20.1M+24% | $23.3M+23% | $27.2M+49% | $27.9M+39% | $31.1M+55% | $33.7M+45% | $33.5M+23% | $31.1M+11% | $32.5M+5% | $31.6M−6% |
| Gross profit | $13.4M+9% | $11.2M+3% | $16.2M+30% | $15.2M+7% | $18.6M+39% | $18.7M+67% | $15.6M−3% | $18.8M+24% | $14.1M−24% | $14.7M−21% | $14.9M−5% | $18.5M−2% |
| $3.6M+63% | −$3.3M | $2.2M+14% | −$1.6M | $807K−78% | −$10.7M+224% | −$4.6M | −$4M+154% | −$1.6M | −$5.2M−51% | $2.3M | −$3.3M−17% | |
| Interest expense | $13K+225% | $30K+150% | $172K+2050% | $370K+36900% | $490K+3669% | $618K+1960% | $583K+239% | $445K+20% | $502K+2% | $617K−0% | $614K+5% | $525K+18% |
| Pre-tax income | $3.6M+66% | $276K+61% | $2M+10% | −$1.8M | $233K−93% | −$18.8M | −$5.1M | −$4.4M+148% | −$2.3M | −$5.9M−69% | $1.7M | −$3.7M−16% |
| $937K+31% | $1.3M | $388K−28% | −$420K | $147K−84% | −$397K | −$1.2M | −$5.2M+1142% | $13.7M+9199% | $356K | $1.3M | $1.2M | |
| Net income | $2.6M+83% | −$977K | $1.7M+25% | −$1.4M | $86K−97% | −$18.4M+1787% | −$3.9M | $766K | −$16M | −$6.2M−66% | $369K | −$4.9M |
| $0.34+79% | −$0.13 | $0.22+22% | −$0.19 | $0.01−97% | −$2.44+1777% | −$0.41 | $0.08 | −$1.64 | −$0.63−74% | $0.04 | −$0.50 | |
| 7.6M−1% | 7.4M−3% | 7.6M+1% | 7.4M−3% | 7.7M+1% | 7.6M+3% | 9.5M+25% | 10.1M+37% | 9.8M+27% | 9.8M+30% | 10.3M+8% | 9.9M−2% |
Revenue: Q1 FY11: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY11: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY11: 6 months less the 3 months printed beside them.
Operating income: Q1 FY11: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY11: 6 months less the 3 months printed beside them.
Income tax: Q1 FY11: 6 months less the 3 months printed beside them.
Net income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
EPS, diluted: 20 periods, Q1 FY11 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY11: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY11 to Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days. 9 periods, Q4 FY12 to Q4 FY26: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY15: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Lakeland Industries' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LAKELakeland Industries | $95.2M | n/m | 20.5× | 0.5× | −0% | −14.0% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| Peer median | $257M | 19.7× | 18.7× | 1.6× | +5% | 6.9% |
More on Lakeland Industries
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .